Research Article

Comparison of Treatment Approaches and Subsequent Outcomes within a Pulmonary Embolism Response Team Registry

Table 2

Secondary outcome 1 (clinical deterioration) by predictors of interest and death.

Predictors of interestNo clinical deterioration (N = 1614)Clinical deterioration (N = 218)Overall (N = 1832)Difference t-test or chi-square, value

PE severity at presentation, N (%)
High risk32 (2.0%)107 (49.1%)139 (7.6%)<0.001
Intermediate-high risk631 (39.1%)76 (34.9%)707 (38.6%)
Intermediate-low risk944 (58.5%)33 (15.1%)977 (53.3%)
Low risk7 (0.4%)2 (0.9%)9 (0.5%)
Bleeding risk assessment, N (%)
High203 (12.6%)45 (20.6%)248 (13.5%)0.006
Moderate812 (50.3%)103 (47.2%)915 (49.9%)
Low599 (37.1%)70 (32.1%)669 (36.5%)

PE severity and bleeding risk profile, N (%)No clinical deterioration (N = 1614)Clinical deterioration (N = 218)Overall (N = 1832)

High PE/high bleeding risk15 (0.9%)19 (8.7%)34 (1.8%)<0.001
High PE/moderate bleeding risk12 (0.7%)50 (22.9%)62 (3.4%)
High PE/low bleeding risk5 (0.3%)38 (17.4%)43 (2.3%)
Intermediate-high PE/high bleeding risk93 (5.8%)20 (9.2%)113 (6.2%)
Intermediate-high PE/moderate bleeding risk319 (19.8%)36 (16.5%)355 (19.4%)
Intermediate-high PE/low bleeding risk219 (13.6%)20 (9.2%)239 (13.0%)
Intermediate-low PE/high bleeding risk95 (5.9%)6 (2.8%)101 (5.5%)
Intermediate-low PE/moderate bleeding risk478 (29.6%)16 (7.3%)494 (27.0%)
Intermediate-low PE/low bleeding risk378 (23.4%)13 (6.0%)391 (21.3%)
Outcome
Death10 (0.6%)84 (38.5%)94 (5.1%)<0.001

The percentages within each cell were calculated using the N in the column header for that cell.